The Development of premix of Erlotinib was done by Murli Krishna Pharma with the aim of overcoming:Poor bio-availability owing to poor solubility and reduction in toxicity through matrix based encapsulation.
The granules are ready for compression. The strength of the granules is 50% w/w. The granules can be employed for compression of tablets having the following strength: 50 mg/tablet (Tablet weight 100 mg) 100 mg/tablet (tablet weight 200 mg) and 150 mg/tablet (tablet weight 300 mg).
We offer development services in case of a requirement for different formulations/dosages/strengths
Offer complete technical package for registrations in all regulated/semi regulated markets
Products protected by ongoing Patents are not offered by MKPPL.